Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Fiserv Inc: A Significant Move in Jeff Auxier's Portfolio
06:09pm, Tuesday, 17'th Feb 2026
Exploring the Strategic Investment Decisions of a Renowned Value Investor Jeff Auxier (Trades, Portfolio) recently submitted the 13F filing for the fourth quar
Orogen Royalties Announces Annual Equity Compensation Grant
07:00pm, Friday, 13'th Feb 2026
VANCOUVER, BC / ACCESS Newswire / February 13, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") announces that, as part of the Company's annual share-based compensation
Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off
12:43pm, Thursday, 12'th Feb 2026
Organon reported disappointing 2025 results, with revenues down 3% and no growth expected in 2026. OGN faces potentially terminal declines in established brands, flat biosimilar growth, and underwhelm
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
11:30am, Thursday, 12'th Feb 2026
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Stree
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
10:44am, Thursday, 12'th Feb 2026
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Organon (OGN) Misses Q4 Earnings and Revenue Estimates
09:50am, Thursday, 12'th Feb 2026
Organon (OGN) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.9 per share a year ago.
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
07:30am, Thursday, 12'th Feb 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.
Brokerages Set Organon & Co. (NYSE:OGN) Target Price at $8.38
01:32am, Sunday, 08'th Feb 2026
Shares of Organon and Co. (NYSE: OGN - Get Free Report) have been given an average rating of "Reduce" by the seven brokerages that are covering the stock, Marketbeat.com reports. Five investment analy
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Monday, 02'nd Feb 2026
Organon (OGN) concluded the recent trading session at $8.2, signifying a -3.98% move from its prior day's close.
Organon Completes Divesture of JADA System to Laborie Medical
02:31pm, Thursday, 29'th Jan 2026
OGN completes JADA System divestiture to Laborie for up to $465M, bolstering its balance sheet and backing debt reduction to fund women's health growth.
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
07:30am, Thursday, 29'th Jan 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST.
Organon Completes Divestiture of JADA® System to Laborie
12:45pm, Wednesday, 28'th Jan 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp.
Orogen Royalties' Exploration Stage Projects and Royalties Update and 2026 Outlook
07:30am, Monday, 26'th Jan 2026
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 26, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded explo
Organon (OGN) Outperforms Broader Market: What You Need to Know
07:00pm, Wednesday, 21'st Jan 2026
Organon (OGN) concluded the recent trading session at $9.59, signifying a +1.37% move from its prior day's close.
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years
12:11pm, Tuesday, 20'th Jan 2026
OGN wins FDA approval to extend NEXPLANON use to five years, backed by trials showing no pregnancies and strong efficacy across body weights.
